13F Holdings
中文EN

TECH BIO-TECHNE Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 842023 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.9%
TTM net income YoY120.5%
TTM EPS YoY124.5%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-11.3%

Margins

Gross margin65.8%
Operating margin19.6%
Net margin14.0%
FCF margin25.1%
EBITDA margin27.5%

Returns

ROE8.3%
ROA6.7%
ROIC (approx.)9.3%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets17.9%
Debt / equity0.00x
Current ratio2.28x
Interest coverage27.16x

Cash quality & payout

Operating cash flow / net income1.96x
Accruals ratio-6.4%
Payout ratio29.1%
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2026*2026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$1.22B$1.22B$1.16B$1.14B$1.11B
Cost of revenue$415.97M$429.36M$389.33M$366.89M$349.10M
Gross profit$799.07M$790.27M$769.73M$769.82M$756.50M
R&D expense$94.77M$99.50M$96.66M$92.49M$87.14M
SG&A expense$452.42M$588.52M$466.38M$378.38M$372.77M
Operating income$251.89M$102.25M$206.69M$298.94M$296.59M
Interest expense$9.63M$8.51M$15.74M$11.21M$11.31M
Pretax income$240.68M$98.46M$185.69M$338.66M$301.39M
Income tax$58.82M$25.06M$17.58M$53.22M$38.29M
Net income$181.86M$73.40M$168.10M$285.26M$272.05M
EBITDA$349.25M$212.16M$318.40M$406.18M$397.66M
EPS (basic)1.170.471.071.811.73
EPS (diluted)1.160.461.051.761.66
Dividends declared per share0.320.320.320.320.32
Weighted avg. shares (diluted)157.01M159.72M160.77M161.85M164.11M
Balance sheet
Cash & equivalents$264.71M$162.19M$151.79M$180.57M$172.57M
Short-term investments——$1.07M$23.74M$74.46M
Receivables$216.59M$206.88M$241.39M$218.47M$194.55M
Inventory$195.74M$189.45M$179.73M$171.64M$141.12M
Current assets$744.40M$608.30M$617.42M$621.48M$605.56M
PP&E, net$231.84M$245.72M$251.15M$226.20M$223.24M
Goodwill$975.36M$980.93M$972.66M$872.74M$822.10M
Intangibles$303.46M$365.60M$507.08M$534.64M$531.52M
Total assets$2.59B$2.56B$2.70B$2.64B$2.29B
Current liabilities$163.70M$175.85M$159.38M$128.51M$176.02M
Short-term debt————$12.50M
Long-term debt$200.00M$346.00M$319.00M$350.00M$243.41M
Total debt$200.00M$346.00M$319.00M$350.00M$255.91M
Total liabilities$478.50M$639.06M$635.02M$672.18M$593.79M
Shareholders' equity$2.11B$1.92B$2.07B$1.97B$1.70B
Net debt-$64.71M$183.81M$167.21M$169.43M$83.34M
Shares outstanding156.10M154.97M158.22M157.64M156.64M
Cash flow statement
Operating cash flow$292.07M$287.56M$298.98M$254.39M$325.27M
Capital expenditure$28.85M$31.01M$62.88M$38.24M$44.91M
Free cash flow$263.22M$256.55M$236.10M$216.15M$280.36M
Investing cash flow-$18.19M-$35.18M-$203.03M-$265.65M-$96.85M
Financing cash flow-$169.11M-$253.91M-$122.40M$22.62M-$242.85M
Depreciation & amortization$97.36M$109.90M$111.71M$107.24M$101.07M
Stock-based compensation$41.37M$40.83M$38.04M$39.23M$42.18M
Dividends paid$49.92M$50.39M$50.42M$50.28M$50.19M
Share buybacks$41.67M$275.73M$80.04M$19.56M$160.95M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.